Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Phase I Study Combining Ibrutinib with Rituximab, Ifosfamide, Carboplatin, and Etoposide (R-ICE) in Patients with Relapsed or Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL): NCI-Cancer Therapeutics Evaluation Program (CTEP) #9588

Craig S. Sauter, MD, Stephanie L. Verwys, Susan J. McCall, MSN ANP-BC, Shoshana T. Miller, Amanda I. Courtien, Heiko Schoder, MD, Pamela Harris, MD, Matthew J. Matasar, MD MS, Anas Younes, MD, Craig H. Moskowitz, MD

Blood (2016) 128 (22): 4198.

https://doi.org/10.1182/blood.V128.22.4198.4198

Published: 2016

Journal Articles

A Phase I Trial of Ibrutinib Plus Palbociclib in Patients with Previously Treated Mantle Cell Lymphoma

Peter Martin, MD, Kristie Blum, MD, Nancy L. Bartlett, MD, Steven I. Park, MD, Kami J. Maddocks, MD, Jia Ruan, MD PhD, Maurizio Di Liberto, PhD, Xiangao Huang, PhD, Giorgio Inghirami, MD, Pamela Harris, MD, Selina Chen-Kiang, PhD, John P. Leonard, MD

Blood (2016) 128 (22): 150.

https://doi.org/10.1182/blood.V128.22.150.150

Published: 2016

Journal Articles

Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor Ibrutinib in Patients with Hairy Cell Leukemia: Stage 1 Results of a Phase 2 Study

Jeffrey Jones, MD MPH, Leslie Andritsos, MD, Robert J. Kreitman, MD, Farhad Ravandi, MD, Charles Schiffer, Timothy G. Call, MD, Gerard Lozanski, MD, Pamela Harris, MD, Jennifer Sexton, Amy S Ruppert, MAS, Michael R. Grever

Blood (2016) 128 (22): 1215.

https://doi.org/10.1182/blood.V128.22.1215.1215

Published: 2016

Journal Articles

Phase I Study of Dose-Adjusted-Teddi-R with Ibrutinib in Untreated and Relapsed/Refractory Primary CNS Lymphoma

Kieron Dunleavy, MD, Catherine E. Lai, MD, Mark Roschewski, MD, Jennifer N Brudno, MD, Brigitte Widemann, MD, Stefania Pittaluga, MD PhD, Elaine S Jaffe, MD, Andrea N Lucas, RN, Maryalice Stetler-Stevenson, MD PhD, Constance M. Yuan, MD PhD, Pamela Harris, MD, Diane Cole, John A Butman, MD, Richard F Little, MD, Louis M Staudt, MD, Wyndham H Wilson, MD PhD

Blood (2015) 126 (23): 472.

https://doi.org/10.1182/blood.V126.23.472.472

Published: 2015

Journal Articles

A Comprehensive Assessment of Phase 1 Clinical Trials in Acute Myeloid Leukemia

Joshua F. Zeidner, MD, Judith E. Karp, MD, Amanda Blackford, Jose Mejias, Gary Smith, S. Percy Ivy, MD, Pamela Harris, MD

Blood (2014) 124 (21): 2282.

https://doi.org/10.1182/blood.V124.21.2282.2282

Published: 2014

Journal Articles

A Dose Escalation Study of Ibrutinib with Lenalidomide for Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Daniel A. Pollyea, MD MS, Steven Coutre, MD, Lia Gore, Nichole Adler, RN, BSN, Pamela Harris, MD, Mitch A. Phelps, PhD, Amy J. Johnson, PhD, YongHua Ling, Hao Li, Jonathan A Gutman, MD, John C. Byrd, MD

Blood (2014) 124 (21): 1987.

https://doi.org/10.1182/blood.V124.21.1987.1987

Published: 2014

NARROW

Phase I Study Combining Ibrutinib with Rituximab, Ifosfamide, Carboplatin, and Etoposide (R-ICE) in Patients with Relapsed or Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL): NCI-Cancer Therapeutics Evaluation Program (CTEP) #9588

A Phase I Trial of Ibrutinib Plus Palbociclib in Patients with Previously Treated Mantle Cell Lymphoma

Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor Ibrutinib in Patients with Hairy Cell Leukemia: Stage 1 Results of a Phase 2 Study

Phase I Study of Dose-Adjusted-Teddi-R with Ibrutinib in Untreated and Relapsed/Refractory Primary CNS Lymphoma

A Comprehensive Assessment of Phase 1 Clinical Trials in Acute Myeloid Leukemia

A Dose Escalation Study of Ibrutinib with Lenalidomide for Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Phase I Study Combining Ibrutinib with Rituximab, Ifosfamide, Carboplatin, and Etoposide (R-ICE) in Patients with Relapsed or Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL): NCI-Cancer Therapeutics Evaluation Program (CTEP) #9588

A Phase I Trial of Ibrutinib Plus Palbociclib in Patients with Previously Treated Mantle Cell Lymphoma

Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor Ibrutinib in Patients with Hairy Cell Leukemia: Stage 1 Results of a Phase 2 Study

Phase I Study of Dose-Adjusted-Teddi-R with Ibrutinib in Untreated and Relapsed/Refractory Primary CNS Lymphoma

A Comprehensive Assessment of Phase 1 Clinical Trials in Acute Myeloid Leukemia

A Dose Escalation Study of Ibrutinib with Lenalidomide for Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only